Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice

Abstract Background Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by an abnormal accumulation of amyloid-β (Aβ) plaques, neuroinflammation, and impaired neurogenesis. Urolithin A (UA), a gut-microbial metabolite of ellagic acid, has been reported to exert anti-in...

Full description

Bibliographic Details
Main Authors: Zhuo Gong, Jingyi Huang, Biao Xu, Zhenri Ou, Le Zhang, Xiaohong Lin, Xiujuan Ye, Xuejian Kong, Dahong Long, Xiangdong Sun, Xiaosong He, Liping Xu, Qingqing Li, Aiguo Xuan
Format: Article
Language:English
Published: BMC 2019-03-01
Series:Journal of Neuroinflammation
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12974-019-1450-3
id doaj-b0c99ea370e64368b59421d4f2a0b91e
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Zhuo Gong
Jingyi Huang
Biao Xu
Zhenri Ou
Le Zhang
Xiaohong Lin
Xiujuan Ye
Xuejian Kong
Dahong Long
Xiangdong Sun
Xiaosong He
Liping Xu
Qingqing Li
Aiguo Xuan
spellingShingle Zhuo Gong
Jingyi Huang
Biao Xu
Zhenri Ou
Le Zhang
Xiaohong Lin
Xiujuan Ye
Xuejian Kong
Dahong Long
Xiangdong Sun
Xiaosong He
Liping Xu
Qingqing Li
Aiguo Xuan
Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice
Journal of Neuroinflammation
Alzheimer’s disease
Urolithin A
Neuroinflammation
Memory impairment
Neurogenesis
author_facet Zhuo Gong
Jingyi Huang
Biao Xu
Zhenri Ou
Le Zhang
Xiaohong Lin
Xiujuan Ye
Xuejian Kong
Dahong Long
Xiangdong Sun
Xiaosong He
Liping Xu
Qingqing Li
Aiguo Xuan
author_sort Zhuo Gong
title Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice
title_short Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice
title_full Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice
title_fullStr Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice
title_full_unstemmed Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice
title_sort urolithin a attenuates memory impairment and neuroinflammation in app/ps1 mice
publisher BMC
series Journal of Neuroinflammation
issn 1742-2094
publishDate 2019-03-01
description Abstract Background Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by an abnormal accumulation of amyloid-β (Aβ) plaques, neuroinflammation, and impaired neurogenesis. Urolithin A (UA), a gut-microbial metabolite of ellagic acid, has been reported to exert anti-inflammatory effects in the brain. However, it is unknown whether UA exerts its properties of anti-inflammation and neuronal protection in the APPswe/PS1ΔE9 (APP/PS1) mouse model of AD. Methods Morris water maze was used to detect the cognitive function. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay was performed to detect neuronal apoptosis. Immunohistochemistry analyzed the response of glia, Aβ deposition, and neurogenesis. The expression of inflammatory mediators were measured by enzyme-linked immunosorbent assay (ELISA) and quantitative real-time polymerase chain reaction (qRT-PCR). The modulating effects of UA on cell signaling pathways were assayed by Western blotting. Results We demonstrated that UA ameliorated cognitive impairment, prevented neuronal apoptosis, and enhanced neurogenesis in APP/PS1 mice. Furthermore, UA attenuated Aβ deposition and peri-plaque microgliosis and astrocytosis in the cortex and hippocampus. We also found that UA affected critical cell signaling pathways, specifically by enhancing cerebral AMPK activation, decreasing the activation of P65NF-κB and P38MAPK, and suppressing Bace1 and APP degradation. Conclusions Our results indicated that UA imparted cognitive protection by protecting neurons from death and triggering neurogenesis via anti-inflammatory signaling in APP/PS1 mice, suggesting that UA might be a promising therapeutic drug to treat AD.
topic Alzheimer’s disease
Urolithin A
Neuroinflammation
Memory impairment
Neurogenesis
url http://link.springer.com/article/10.1186/s12974-019-1450-3
work_keys_str_mv AT zhuogong urolithinaattenuatesmemoryimpairmentandneuroinflammationinappps1mice
AT jingyihuang urolithinaattenuatesmemoryimpairmentandneuroinflammationinappps1mice
AT biaoxu urolithinaattenuatesmemoryimpairmentandneuroinflammationinappps1mice
AT zhenriou urolithinaattenuatesmemoryimpairmentandneuroinflammationinappps1mice
AT lezhang urolithinaattenuatesmemoryimpairmentandneuroinflammationinappps1mice
AT xiaohonglin urolithinaattenuatesmemoryimpairmentandneuroinflammationinappps1mice
AT xiujuanye urolithinaattenuatesmemoryimpairmentandneuroinflammationinappps1mice
AT xuejiankong urolithinaattenuatesmemoryimpairmentandneuroinflammationinappps1mice
AT dahonglong urolithinaattenuatesmemoryimpairmentandneuroinflammationinappps1mice
AT xiangdongsun urolithinaattenuatesmemoryimpairmentandneuroinflammationinappps1mice
AT xiaosonghe urolithinaattenuatesmemoryimpairmentandneuroinflammationinappps1mice
AT lipingxu urolithinaattenuatesmemoryimpairmentandneuroinflammationinappps1mice
AT qingqingli urolithinaattenuatesmemoryimpairmentandneuroinflammationinappps1mice
AT aiguoxuan urolithinaattenuatesmemoryimpairmentandneuroinflammationinappps1mice
_version_ 1724924583606222848
spelling doaj-b0c99ea370e64368b59421d4f2a0b91e2020-11-25T02:09:19ZengBMCJournal of Neuroinflammation1742-20942019-03-0116111310.1186/s12974-019-1450-3Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 miceZhuo Gong0Jingyi Huang1Biao Xu2Zhenri Ou3Le Zhang4Xiaohong Lin5Xiujuan Ye6Xuejian Kong7Dahong Long8Xiangdong Sun9Xiaosong He10Liping Xu11Qingqing Li12Aiguo Xuan13Institute of Neuroscience and Department of Neurology of the Second Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of ChinaInstitute of Neuroscience and Department of Neurology of the Second Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of ChinaInstitute of Neuroscience and Department of Neurology of the Second Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of ChinaInstitute of Neuroscience and Department of Neurology of the Second Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of ChinaInstitute of Neuroscience and Department of Neurology of the Second Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of ChinaInstitute of Neuroscience and Department of Neurology of the Second Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of ChinaInstitute of Neuroscience and Department of Neurology of the Second Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of ChinaDepartment of Neurology of the Sixth Affiliated Hospital, Guangzhou Medical UniversityInstitute of Neuroscience and Department of Neurology of the Second Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of ChinaInstitute of Neuroscience and Department of Neurology of the Second Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of ChinaInstitute of Neuroscience and Department of Neurology of the Second Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of ChinaInstitute of Neuroscience and Department of Neurology of the Second Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of ChinaInstitute of Neuroscience and Department of Neurology of the Second Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of ChinaInstitute of Neuroscience and Department of Neurology of the Second Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of ChinaAbstract Background Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by an abnormal accumulation of amyloid-β (Aβ) plaques, neuroinflammation, and impaired neurogenesis. Urolithin A (UA), a gut-microbial metabolite of ellagic acid, has been reported to exert anti-inflammatory effects in the brain. However, it is unknown whether UA exerts its properties of anti-inflammation and neuronal protection in the APPswe/PS1ΔE9 (APP/PS1) mouse model of AD. Methods Morris water maze was used to detect the cognitive function. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay was performed to detect neuronal apoptosis. Immunohistochemistry analyzed the response of glia, Aβ deposition, and neurogenesis. The expression of inflammatory mediators were measured by enzyme-linked immunosorbent assay (ELISA) and quantitative real-time polymerase chain reaction (qRT-PCR). The modulating effects of UA on cell signaling pathways were assayed by Western blotting. Results We demonstrated that UA ameliorated cognitive impairment, prevented neuronal apoptosis, and enhanced neurogenesis in APP/PS1 mice. Furthermore, UA attenuated Aβ deposition and peri-plaque microgliosis and astrocytosis in the cortex and hippocampus. We also found that UA affected critical cell signaling pathways, specifically by enhancing cerebral AMPK activation, decreasing the activation of P65NF-κB and P38MAPK, and suppressing Bace1 and APP degradation. Conclusions Our results indicated that UA imparted cognitive protection by protecting neurons from death and triggering neurogenesis via anti-inflammatory signaling in APP/PS1 mice, suggesting that UA might be a promising therapeutic drug to treat AD.http://link.springer.com/article/10.1186/s12974-019-1450-3Alzheimer’s diseaseUrolithin ANeuroinflammationMemory impairmentNeurogenesis